Novo Nordisk announced positive Phase 3 results for denecimig (Mim8), an investigational hemophilia A treatment. The company presented the FRONTIER4 long-term extension study data at the ISTH 2026 Congress.
The study demonstrated long-term safety and efficacy for adults, adolescents, and children. The prophylaxis treatment showed effectiveness in patients both with and without inhibitors.
The open-label FRONTIER4 trial includes 426 patients from previous clinical studies. These results support the drug's potential in a competitive market.
This clinical success aids Novo Nordisk's expansion into rare diseases. The company aims to grow beyond its core diabetes and obesity franchises.